276 related articles for article (PubMed ID: 34463610)
1. Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results.
Wing K; Williamson E; Carpenter JR; Wise L; Schneeweiss S; Smeeth L; Quint JK; Douglas I
Health Technol Assess; 2021 Aug; 25(51):1-70. PubMed ID: 34463610
[TBL] [Abstract][Full Text] [Related]
2. Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials.
Wing K; Williamson E; Carpenter JR; Wise L; Schneeweiss S; Smeeth L; Quint JK; Douglas I
Eur Respir J; 2021 Mar; 57(3):. PubMed ID: 33093119
[TBL] [Abstract][Full Text] [Related]
3. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
[TBL] [Abstract][Full Text] [Related]
4. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Nannini LJ; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD006829. PubMed ID: 22972099
[TBL] [Abstract][Full Text] [Related]
5. Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results.
Wing K; Williamson E; Carpenter JR; Wise L; Schneeweiss S; Smeeth L; Quint JK; Douglas I
BMJ Open; 2018 Mar; 8(3):e019475. PubMed ID: 29581202
[TBL] [Abstract][Full Text] [Related]
6. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
Welsh EJ; Cates CJ; Poole P
Cochrane Database Syst Rev; 2013 May; (5):CD007891. PubMed ID: 23728670
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.
Robinson DE; Ali MS; Strauss VY; Elhussein L; Abrahamsen B; Arden NK; Ben-Shlomo Y; Caskey F; Cooper C; Dedman D; Delmestri A; Judge A; Javaid MK; Prieto-Alhambra D
Health Technol Assess; 2021 Mar; 25(17):1-106. PubMed ID: 33739919
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
10. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
Welsh EJ; Cates CJ; Poole P
Cochrane Database Syst Rev; 2010 May; (5):CD007891. PubMed ID: 20464758
[TBL] [Abstract][Full Text] [Related]
11. Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.
Ohar JA; Crater GD; Emmett A; Ferro TJ; Morris AN; Raphiou I; Sriram PS; Dransfield MT
Respir Res; 2014 Sep; 15(1):105. PubMed ID: 25248764
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
Chong J; Karner C; Poole P
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009157. PubMed ID: 22972134
[TBL] [Abstract][Full Text] [Related]
14. Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.
Nannini LJ; Poole P; Milan SJ; Holmes R; Normansell R
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD003794. PubMed ID: 24214176
[TBL] [Abstract][Full Text] [Related]
15. Varenicline versus nicotine replacement therapy for long-term smoking cessation: an observational study using the Clinical Practice Research Datalink.
Davies NM; Taylor AE; Taylor GM; Itani T; Jones T; Martin RM; Munafò MR; Windmeijer F; Thomas KH
Health Technol Assess; 2020 Feb; 24(9):1-46. PubMed ID: 32079557
[TBL] [Abstract][Full Text] [Related]
16. Vilanterol and fluticasone furoate for asthma.
Dwan K; Milan SJ; Bax L; Walters N; Powell C
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD010758. PubMed ID: 27582089
[TBL] [Abstract][Full Text] [Related]
17. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
[TBL] [Abstract][Full Text] [Related]
18. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
O'Shea O; Stovold E; Cates CJ
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD007694. PubMed ID: 33852162
[TBL] [Abstract][Full Text] [Related]
19. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
